Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice.
about
Chloroquine and hydroxychloroquine for cancer therapyTrial Watch:: Oncolytic viruses for cancer therapyTrial Watch-Oncolytic viruses and cancer therapyChemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide.CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma modelAntitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.Immunological suppression of head and neck carcinoma by dendritic cell tumor fusion vaccine.Immunostimulatory activity of lifespan-extending agents.Metronomics: towards personalized chemotherapy?Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12.SPARC (secreted protein acidic and rich in cysteine) knockdown protects mice from acute liver injury by reducing vascular endothelial cell damage.Current trends of anticancer immunochemotherapy.Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.T cell homing therapy for reducing regulatory T cells and preserving effector T cell function in large solid tumors.Trial watch: Chemotherapy with immunogenic cell death inducers.
P2860
Q26827797-D456E847-5F1A-486F-8292-9B425FC024C2Q27021951-A535A88C-C51B-4FA9-81C1-034001F50593Q28072347-9601D43B-18E4-4708-B529-CB834C9F2B86Q36476117-A82DAA91-C0E8-4BBA-AD1A-A1949C14CFD0Q36600960-4F9B592A-AB15-4FA1-8C99-15841015A359Q36707865-034DF352-7095-4643-8B98-C527820A257AQ37325047-4E9A0141-461B-4D3D-BD73-A1F4B67AC29DQ38175673-49104140-3322-44C8-B610-99757F638CEDQ38218923-129E247B-54F6-4EBB-8FCF-482EC0EF02ECQ38703318-A603B1FD-D253-4C14-B81F-351B0DC0E954Q40111377-A631D9FB-56F9-4031-86FC-BD06C86BDB05Q43084689-DC13C520-9C95-4731-8FB7-8747BE64B3ABQ48508291-FE872EDA-F63A-48B6-9BDD-5B4A2CC7DB33Q49390588-34B1990A-5201-465B-8B40-62D1045131CAQ55658029-1222F351-B507-41DA-B4B2-80DD554451C7
P2860
Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Single low-dose cyclophosphami ...... colorectal carcinoma in mice.
@ast
Single low-dose cyclophosphami ...... colorectal carcinoma in mice.
@en
type
label
Single low-dose cyclophosphami ...... colorectal carcinoma in mice.
@ast
Single low-dose cyclophosphami ...... colorectal carcinoma in mice.
@en
prefLabel
Single low-dose cyclophosphami ...... colorectal carcinoma in mice.
@ast
Single low-dose cyclophosphami ...... colorectal carcinoma in mice.
@en
P2093
P2860
P356
P1433
P1476
Single low-dose cyclophosphami ...... t colorectal carcinoma in mice
@en
P2093
Catalina Atorrasagasti
Esteban Fiore
Flavia Piccioni
Guillermo Mazzolini
Laura Alaniz
Mariana Garcia
Mariana Malvicini
Pablo Matar
P2860
P304
P356
10.4161/ONCI.20684
P577
2012-10-01T00:00:00Z